Natera, Inc. (NASDAQ:NTRA) Shares Bought by Northern Trust Corp

Northern Trust Corp lifted its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 30.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 700,781 shares of the medical research company's stock after purchasing an additional 163,739 shares during the period. Northern Trust Corp owned about 0.53% of Natera worth $110,934,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in NTRA. Blue Trust Inc. increased its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares during the period. Versant Capital Management Inc grew its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares during the period. Principal Securities Inc. raised its position in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 6,980 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the transaction, the chief executive officer now owns 185,182 shares of the company's stock, valued at approximately $27,795,818.20. The trade was a 3.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,562 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the sale, the chief financial officer now directly owns 75,557 shares in the company, valued at $10,457,844.37. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 196,601 shares of company stock worth $29,831,575. Insiders own 7.60% of the company's stock.

Analyst Ratings Changes

NTRA has been the subject of a number of research reports. Barclays reduced their target price on shares of Natera from $200.00 to $160.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Piper Sandler lifted their target price on Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Sanford C. Bernstein upped their price target on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Friday, January 10th. Guggenheim lifted their price objective on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research report on Friday, January 17th. Finally, The Goldman Sachs Group upped their price objective on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $175.76.

Natera Stock Performance

NTRA opened at $156.66 on Friday. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The stock has a market cap of $21.18 billion, a P/E ratio of -89.01 and a beta of 1.80. The stock's 50 day simple moving average is $146.93 and its 200 day simple moving average is $154.37. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. As a group, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.